143 related articles for article (PubMed ID: 16421458)
1. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations.
Aichhorn W; Marksteiner J; Walch T; Zernig G; Saria A; Kemmler G
Int Clin Psychopharmacol; 2006 Mar; 21(2):81-5. PubMed ID: 16421458
[TBL] [Abstract][Full Text] [Related]
2. Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service.
Castberg I; Skogvoll E; Spigset O
J Clin Psychiatry; 2007 Oct; 68(10):1540-5. PubMed ID: 17960969
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients.
Bakken GV; Rudberg I; Molden E; Refsum H; Hermann M
Ther Drug Monit; 2011 Apr; 33(2):222-6. PubMed ID: 21383647
[TBL] [Abstract][Full Text] [Related]
4. Interactions between valproic acid and quetiapine/olanzapine in the treatment of bipolar disorder and the role of therapeutic drug monitoring.
Vella T; Mifsud J
J Pharm Pharmacol; 2014 Jun; 66(6):747-59. PubMed ID: 24392714
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders.
McConville BJ; Arvanitis LA; Thyrum PT; Yeh C; Wilkinson LA; Chaney RO; Foster KD; Sorter MT; Friedman LM; Brown KL; Heubi JE
J Clin Psychiatry; 2000 Apr; 61(4):252-60. PubMed ID: 10830145
[TBL] [Abstract][Full Text] [Related]
6. Results of a naturalistic study of treatment options: switching atypical antipsychotic drugs or augmenting with valproate.
Cramer JA; Sernyak M
Clin Ther; 2004 Jun; 26(6):905-14. PubMed ID: 15262461
[TBL] [Abstract][Full Text] [Related]
7. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Henderson DC; Copeland PM; Borba CP; Daley TB; Nguyen DD; Cagliero E; Evins AE; Zhang H; Hayden DL; Freudenreich O; Cather C; Schoenfeld DA; Goff DC
J Clin Psychiatry; 2006 May; 67(5):789-97. PubMed ID: 16841629
[TBL] [Abstract][Full Text] [Related]
8. Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders.
Winter HR; Earley WR; Hamer-Maansson JE; Davis PC; Smith MA
J Child Adolesc Psychopharmacol; 2008 Feb; 18(1):81-98. PubMed ID: 18294091
[TBL] [Abstract][Full Text] [Related]
9. Possible drug-drug interaction between quetiapine and lamotrigine--evidence from a Swedish TDM database.
Andersson ML; Björkhem-Bergman L; Lindh JD
Br J Clin Pharmacol; 2011 Jul; 72(1):153-6. PubMed ID: 21651616
[TBL] [Abstract][Full Text] [Related]
10. Cingulate gyrus volumetry in drug free bipolar patients and patients treated with valproate or valproate and quetiapine.
Atmaca M; Ozdemir H; Cetinkaya S; Parmaksiz S; Belli H; Poyraz AK; Tezcan E; Ogur E
J Psychiatr Res; 2007 Nov; 41(10):821-7. PubMed ID: 16950400
[TBL] [Abstract][Full Text] [Related]
11. Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder.
Winter HR; DeVane CL; Figueroa C; Ennis DJ; Hamer-Maansson JE; Davis PC; Smith MA
Hum Psychopharmacol; 2007 Oct; 22(7):469-76. PubMed ID: 17729385
[TBL] [Abstract][Full Text] [Related]
12. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine.
Wong YW; Yeh C; Thyrum PT
J Clin Psychopharmacol; 2001 Feb; 21(1):89-93. PubMed ID: 11199955
[TBL] [Abstract][Full Text] [Related]
13. Quetiapine fumarate for schizophrenia and bipolar disorder in young patients.
Ribolsi M; Magni V; Rubino IA
Drugs Today (Barc); 2010 Aug; 46(8):581-7. PubMed ID: 20830318
[TBL] [Abstract][Full Text] [Related]
14. Quetiapine alone and added to a mood stabilizer for serious mood disorders.
Sajatovic M; Brescan DW; Perez DE; DiGiovanni SK; Hattab H; Ray JB; Bingham CR
J Clin Psychiatry; 2001 Sep; 62(9):728-32. PubMed ID: 11681770
[TBL] [Abstract][Full Text] [Related]
15. Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study.
Mamo DC; Uchida H; Vitcu I; Barsoum P; Gendron A; Goldstein J; Kapur S
J Clin Psychiatry; 2008 Jan; 69(1):81-6. PubMed ID: 18312041
[TBL] [Abstract][Full Text] [Related]
16. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia.
Gefvert O; Bergström M; Långström B; Lundberg T; Lindström L; Yates R
Psychopharmacology (Berl); 1998 Jan; 135(2):119-26. PubMed ID: 9497016
[TBL] [Abstract][Full Text] [Related]
17. Plasma concentrations of quetiapine, N-desalkylquetiapine, o-desalkylquetiapine, 7-hydroxyquetiapine, and quetiapine sulfoxide in relation to quetiapine dose, formulation, and other factors.
Fisher DS; Handley SA; Flanagan RJ; Taylor DM
Ther Drug Monit; 2012 Aug; 34(4):415-21. PubMed ID: 22777152
[TBL] [Abstract][Full Text] [Related]
18. Quetiapine and classical mood stabilizers in the long-term treatment of Bipolar Disorder: a 4-year follow-up naturalistic study.
Altamura AC; Mundo E; Dell'Osso B; Tacchini G; Buoli M; Calabrese JR
J Affect Disord; 2008 Sep; 110(1-2):135-41. PubMed ID: 18329720
[TBL] [Abstract][Full Text] [Related]
19. Single-dose relative bioavailability of a new quetiapine fumarate extended-release formulation: a postprandial, randomized, open-label, two-period crossover study in healthy Uruguayan volunteers.
Estevez-Carrizo FE; Parrillo S; Ercoli MC; Estevez-Parrillo FT
Clin Ther; 2011 Jun; 33(6):738-45. PubMed ID: 21704238
[TBL] [Abstract][Full Text] [Related]
20. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
